scholarly journals Enhanced absorption of hydroxysafflor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies

2012 ◽  
pp. 4099 ◽  
Author(s):  
Min Han ◽  
Chen-Qi Tong ◽  
Lv ◽  
Lv ◽  
Tang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
In Vivo Studies ◽  
Hydroxysafflor Yellow A ◽  
Enhanced Absorption

Novel Self-Micro Emulsifying Drug Delivery System for safe intra muscular delivery with improved pharmacodynamics and pharmacokinetics

2021 ◽  
Vol 18 ◽  
Author(s):  
Subheet Kumar Jain ◽  
Neha Panchal ◽  
Amrinder Singh ◽  
Shubham Thakur ◽  
Navid Reza Shahtaghi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Inflammatory Diseases ◽  
Diclofenac Sodium ◽  
Physical Stability ◽  
In Vivo Studies ◽  
High Concentration

Background: Diclofenac sodium (DS) injection is widely used in the management of acute or chronic pain and inflammatory diseases. It incorporates 20 % w/v Transcutol-P as a solubilizer to make the stable injectable formulation. However, the use of Transcutol-P in high concentration leads to adverse effects such as severe nephrotoxicity, etc. Some advancements resulted in the formulation of an aqueous based injectable but that too used benzyl alcohol reported to be toxic for human use. Objective: To develop an injectable self-micro emulsifying drug delivery system (SMEDDS) as a novel carrier of DS for prompt release with better safety and efficacy. Methods: A solubility study was performed with different surfactants and co-surfactants. The conventional stirring method was employed for the formulation of SMEDDS. Detailed in vitro characterization was done for different quality control parameters. In vivo studies were performed using Wistar rats for pharmacokinetic evaluation, toxicological analysis, and analgesic activity. Results: The optimized formulation exhibited good physical stability, ideal globule size (156±0.4 nm), quick release, better therapeutics, and safety, increase in LD50 (221.9 mg/kg) to that of the commercial counterpart (109.9 mg/kg). Further, pre-treatment with optimized formulation reduced the carrageenan-induced rat paw oedema by 88±1.2 % after 4 h, compared to 77±1.6 % inhibition with commercial DS formulation. Moreover, optimized formulation significantly (p<0.05) inhibited the pain sensation in the acetic-acid induced writhing test in mice compared to its commercial equivalent with a better pharmacokinetic profile. Conclusion: The above findings confirmed that liquid SMEDDS could be a successful carrier for the safe and effective delivery of DS

Niosomes as transdermal drug delivery system for celecoxib: in vitro and in vivo studies

2015 ◽  
Vol 73 (5) ◽  
pp. 1229-1245 ◽  
Author(s):  
Sayed H. Auda ◽  
Dina Fathalla ◽  
Gihan Fetih ◽  
Mahmoud El-Badry ◽  
Faiyaz Shakeel
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Transdermal Drug Delivery ◽  
In Vivo Studies ◽  
Transdermal Drug Delivery System

An Implantable Microfabricated Drug Delivery System

2003 ◽  
Author(s):  
John M. Maloney
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
In Vivo Studies ◽  
Multiple Drug ◽  
Hermetic Storage ◽  
Continuous Release ◽  
One Year

We report on the development of a fully implantable drug delivery system capable of delivering hundreds of individual doses. This product is intended for the controlled release of potent therapeutic compounds that might otherwise require frequent injections. Our system has the following capabilities: • Stable, hermetic storage of therapeutic drugs in solid, liquid, or gel form; • Individual storage of discrete doses for multiple-drug regimens; • Wireless communication with an external controller for device monitoring and therapy modification; • Choice of preprogrammed release or release on command; • Controlled pulsatile or continuous release. MicroCHIPS’ drug release technology has been successfully demonstrated in vitro and in vivo. We are proceeding with long-term in vivo studies of a fully implantable device containing one hundred individual doses. A future device intended for human clinical trials will contain four hundred doses, enough for a daily release of drug for more than one year.

Formulation and evaluation of α-Pinene loaded Self-emulsifying nanoformulation for in-vivo anti-Parkinson’s activity

2021 ◽  
Vol 15 ◽  
Author(s):  
Rajnish Srivastava ◽  
P.K. Choudhury ◽  
Suresh Kumar Dev ◽  
Vaibhav Rathore
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Neuroprotective Effect ◽  
Spherical Shape ◽  
Tween 80 ◽  
In Vivo Studies ◽  
Drug Release Profile

Aim: The aim of the present study was to develop and optimize the self-nanoemulsifying drug delivery system of α-pinene (ALP-SNEDDS) and to evaluate its in-vivo anti-Parkinson’s activity. Background: Different lipid-based drug delivery technologies have been researched to upgrade the bioavailability of such drug candidates and to expand their clinical adequacy upon oral administration. Self-emulsifying drug delivery system (SEDDS) have pulled in expanding interests and, specifically, self-nanoemulsifying drug delivery system (SNEDDS). Objective: The present work was an attempt in order to improve the bioavailability of the ALP via defining the role of self-nanoemulsifying formulations for its neuroprotective effect. Method: Miscibility of the ALP was estimated in various excipient components to select the optimized combination. Self-nanoemulsification, thermodynamic stability, effect of dilution on robustness, optical clarity, viscosity and conductivity tests were performed. The in-vivo anti-Parkinson’s activity of the ALP-SNEEDS formulations were done by using Pilocarpine antagonism induced Parkinsonism in rodents. Behavioural tests like tremulous jaw movements, body temperature, salivation and lacrimation are performed. Result: Two optimized formulation, composed of Anise oil, Tween 80 and Transcutol-HP of Oil: Smix ratio (4:6 and 3:7) were selected. The Smix ratio for both the formulation was 2:1. The particle size was found to consistent with the increase in dilution. The mean negative zeta potential of the formulations was found to be increased with increase in dilution. The TEM images of the formulations reveals spherical shape of the droplet. The in-vitro drug release profile was found to be significant as compared to plain ALP suspension. Conclusion: The results form in-vivo studies indicate that nanosizing and enhanced solubilisation of oral ALP-SNEDDS formulations significantly improved the behavioural activities as compared to plain ALP suspension.

scholarly journals Bioavailability of Tea Catechins and Its Improvement

Molecules ◽  
2018 ◽  
Vol 23 (9) ◽  
pp. 2346 ◽  
Author(s):  
Zhuo-Yu Cai ◽  
Xu-Min Li ◽  
Jin-Pei Liang ◽  
Li-Ping Xiang ◽  
Kai-Rong Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Laboratory Tests ◽  
In Vivo Studies ◽  
Tea Catechins ◽  
Beneficial Effects ◽  
Molecular Modification

Many in vitro studies have shown that tea catechins had vevarious health beneficial effects. However, inconsistent results between in vitro and in vivo studies or between laboratory tests and epidemical studies are observed. Low bioavailability of tea catechins was an important factor leading to these inconsistencies. Research advances in bioavailability studies involving absorption and metabolic biotransformation of tea catechins were reviewed in the present paper. Related techniques for improving their bioavailability such as nanostructure-based drug delivery system, molecular modification, and co-administration of catechins with other bioactives were also discussed.

Sign in / Sign up

Export Citation Format

Share Document